BACKGROUND: We aimed to estimate the effect of anti-retroviral therapy (ART) on incident tuberculosis (TB) in a cohort of HIV-infected children. METHODS: We analysed data from ART-naïve, TB disease-free children enrolled between December 2004 and April 2008 into an HIV care program in Kinshasa, Democratic Republic of Congo. To estimate the effect of ART on TB incidence while accounting for time-dependent confounders affected by exposure, a Cox proportional hazards marginal structural model was used. RESULTS: 364 children contributed 596.0 person-years of follow-up. At baseline, the median age was 6.9 years; 163 (44.8%) were in HIV clinical stage 3 or 4. During follow-up, 242 (66.5%) children initiated ART and 81 (22.3%) developed TB. At TB diagnosis, 41 (50.6%) were receiving ART. The TB incidence rate in those receiving ART was 10.2 per 100 person-years [95% confidence interval (CI) 7.4-13.9] compared with 20.4 per 100 person-years (95% CI 14.6-27.8) in those receiving only primary HIV care. TB incidence decreased with time on ART, from 18.9 per 100 person-years in the first 6 months to 5.3 per 100 person-years after 12 months of ART. The model-estimated TB hazard ratio for ART was 0.51 (95% CI 0.27-0.94). CONCLUSIONS: For HIV-infected children in TB-endemic areas, ART reduces the hazard of developing TB by 50%.
BACKGROUND: We aimed to estimate the effect of anti-retroviral therapy (ART) on incident tuberculosis (TB) in a cohort of HIV-infectedchildren. METHODS: We analysed data from ART-naïve, TB disease-free children enrolled between December 2004 and April 2008 into an HIV care program in Kinshasa, Democratic Republic of Congo. To estimate the effect of ART on TB incidence while accounting for time-dependent confounders affected by exposure, a Cox proportional hazards marginal structural model was used. RESULTS: 364 children contributed 596.0 person-years of follow-up. At baseline, the median age was 6.9 years; 163 (44.8%) were in HIV clinical stage 3 or 4. During follow-up, 242 (66.5%) children initiated ART and 81 (22.3%) developed TB. At TB diagnosis, 41 (50.6%) were receiving ART. The TB incidence rate in those receiving ART was 10.2 per 100 person-years [95% confidence interval (CI) 7.4-13.9] compared with 20.4 per 100 person-years (95% CI 14.6-27.8) in those receiving only primary HIV care. TB incidence decreased with time on ART, from 18.9 per 100 person-years in the first 6 months to 5.3 per 100 person-years after 12 months of ART. The model-estimated TB hazard ratio for ART was 0.51 (95% CI 0.27-0.94). CONCLUSIONS: For HIV-infectedchildren in TB-endemic areas, ART reduces the hazard of developing TB by 50%.
Authors: Y Yazdanpanah; G Chêne; E Losina; S J Goldie; L D Merchadou; S Alfandari; G R Seage; L Sullivan; C Marimoutou; A D Paltiel; R Salamon; Y Mouton; K A Freedberg Journal: Int J Epidemiol Date: 2001-08 Impact factor: 7.196
Authors: A Kouakoussui; P Fassinou; M F Anaky; N Elenga; R Laguide; M L Wemin; R Toure; H Menan; F Rouet; P Msellati Journal: Paediatr Respir Rev Date: 2004-12 Impact factor: 2.726
Authors: Tamara Flys; Dwight V Nissley; Cassidy W Claasen; Dana Jones; Chanjuan Shi; Laura A Guay; Philippa Musoke; Francis Mmiro; Jeffrey N Strathern; J Brooks Jackson; James R Eshleman; Susan H Eshleman Journal: J Infect Dis Date: 2005-06-01 Impact factor: 5.226
Authors: L L Abuogi; C Mwachari; H H Leslie; S B Shade; J Otieno; N Yienya; L Sanguli; E Amukoye; C R Cohen Journal: Int J Tuberc Lung Dis Date: 2013-10 Impact factor: 2.373
Authors: April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling Journal: J Acquir Immune Defic Syndr Date: 2011-08-01 Impact factor: 3.731
Authors: S Janssen; M A M Huson; S Bélard; S Stolp; N Kapata; M Bates; M van Vugt; M P Grobusch Journal: Infection Date: 2013-12-06 Impact factor: 3.553
Authors: A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch Journal: HIV Med Date: 2015-02-03 Impact factor: 3.180
Authors: L Fenner; M Forster; A Boulle; S Phiri; P Braitstein; C Lewden; M Schechter; N Kumarasamy; M Pascoe; E Sprinz; D R Bangsberg; P S Sow; D Dickinson; M P Fox; J McIntyre; M Khongphatthanayothin; F Dabis; M W G Brinkhof; R Wood; M Egger Journal: Int J Tuberc Lung Dis Date: 2011-05 Impact factor: 2.373
Authors: Loukia Aketi; Pierre M Tshibassu; Patrick K Kayembe; Faustin Kitetele; Samuel Edidi; Mathilde B Ekila; Roger Wumba; François B Lepira; Michel N Aloni Journal: Pathog Glob Health Date: 2015-07-17 Impact factor: 2.894